To further confirm our overall observations, we performed an analysis using a TMA containing samples from triple-negative breast cancer patients with stage I–III breast cancers, to analyze the levels of pT654 EGFR throughout different stages of disease. This evidence concerns the gene EGFR and triple-negative breast carcinoma.